About MediBuddy
MediBuddy is a publicly listed company based in Bengaluru (India) founded in 2013 by Enbasekar D and Satish Kannan, and was acquired by DocsApp in June 2020. MediBuddy has raised $199.22 million across 15 funding rounds from investors including DeNA, Bessemer Venture Partners and DocsApp. The company has 52 employees. MediBuddy has completed 2 acquisitions, including Clinix and MediBuddy VHealth. MediBuddy was last valued at $418.14 million in February 2023. Its chief executive, as recorded, is Satish Kannan. Its website medibuddy.in draws about 1.4 million monthly visits. Its Indian entity Medi Assist Healthcare Services Limited reported revenue of βΉ924 Cr. Its focus areas include HealthTech, Healthcare Booking Platforms and Diversified. Its competitors include Practo, API Holdings and Mfine; 3 of its 3 listed competitors have raised funding.
Company details
Online platform offering multiple healthcare services. The platform enables users to search for healthcare providers and schedule follow-ups with doctors across multiple medical specialties. Also, it enables users to access medicine delivery, lab tests, health check-up, and insurance services.
- Headquarters Bengaluru, India
- Employees 52
- Founders Enbasekar D, Satish Kannan
- Stage Acquired
- SectorsHealthcare
- Website category Finance · Insurance
- Phoneβ’β’β’β’ β’β’β’β’
- Website medibuddy.in
- Social LinkedIn X Facebook
- Acquired by DocsApp (Jun 2020)
- Legal Name Medi Assist Healthcare Services Limited
- Date of Incorporation 07 Jun, 2000
- Jurisdiction Mumbai, Maharashtra, India
- Market Cap₹2,156 Cr
MEDIASSIST · NSE
- Share Price₹284.15
-1.54% today
- Revenue₹905 Cr
FY 2025-26 · +25.1% YoY
- EBITDA₹160 Cr
Margin 17.7%
- Net Profit₹96.22 Cr
FY 2025-26 · +9.3% YoY
- P/E (TTM)22.1x
P/B 2.7x
- Total Equity Funding$199.22M (USD)
in 15 rounds
- Latest Funding Round$5.9M (USD), Series C
Jan 2026
- InvestorsDeNA
& 52 more
- Employee Count52
- Investments & AcquisitionsClinix
& 1 more
- Acquired byDocsApp
(Jun 2020)
Associated legal entities of MediBuddy
MediBuddy is associated with 2 registered companies on The Company Check; the primary company is Medi Assist Healthcare Services Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Medi Assist Healthcare Services Limited Listed CIN L74900MH2000PLC437885 | Active | 07 Jun 2000 | Mumbai, Maharashtra | ₹924 Cr | 134 | 11 | View details |
| Phasorz Technologies Private Limited CIN U72300TN2013PTC092385 | Active | 31 Jul 2013 | Chennai, Tamil Nadu | ₹743 Cr | 927 | 7 | View details |
Apps and channels of MediBuddy
MediBuddy publishes 1 mobile app with over 5M+ downloads.
Funding Insights of MediBuddy
MediBuddy has successfully raised a total of $199.22M across 15 strategic funding rounds. The most recent funding activity was a Series C round of $5.9 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $199.22M
- Total Rounds 15
- Last Round Series C β $5.9M
- First Round $232,937
(Mar 2014)
- Investors Count 52
Latest 10 of 15 funding rounds of MediBuddy with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $5.9M | Series C | β | BlackSoil | |
| May 2024 | $8.4M | Debt – Venture | β | β | |
| Feb 2023 | $18.86M | Series C | $418.14M | Zenith Investment Partners | |
| Feb 2022 | $125M | Series C | $334.01M | Quadria Capital, Lightrock India | |
| Oct 2021 | $885,859 | Series B | $β’β’β’β’β’ | Stride Ventures | |
| Jun 2021 | $3.43M | Debt – Venture | β | β | |
| Feb 2021 | $3.43M | Debt – Conventional | β | β | |
| May 2020 | $40M | Series B | $β’β’β’β’β’ | InvAscent, Ales | |
| Oct 2018 | $20,412 | Angel Round | $β’β’β’β’β’ | Ashok Kumar Sarojananjundan | β |
| Oct 2017 | $6.03M | Series A | $β’β’β’β’β’ | Bessemer Venture Partners |
| Date | Valuation | Stage |
|---|---|---|
| Feb 2023 | $418.14M | β’β’β’β’β’β’β’β’ |
| Feb 2022 | $334.01M | β’β’β’β’β’β’β’β’ |
| Oct 2021 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| May 2020 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| Oct 2018 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| Oct 2017 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| May 2017 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| May 2016 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
Full valuation and stage history of MediBuddy
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $418.14M (Feb 2023). 53 investors in total: 30 institutional and 23 angel.
Investors in MediBuddy
MediBuddy has secured backing from 53 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include DeNA, Bessemer Venture Partners and DocsApp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is extended to companies across multiple sectors. | 2008 | innovencapital.com | Mumbai, India | |
Venture debt funding and structured finance for innovative startups in India. | 2018 | alteriacapital.com | Mumbai, India | |
Healthcare private equity investments focused on Asian markets. | 2012 | quadriacapital.com | Singapore, Singapore | |
Investments are directed toward growth-stage companies generating scalable impact. | 2009 | lightrock.com | London, United Kingdom | |
Venture debt is provided to growth-stage companies for business scaling. | strideventures.global | Delhi, India | ||
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
Investments in early-stage tech startups are made by JAFCO Asia. | jafcoasia.com | Singapore, Singapore | ||
Early-stage venture capital firm focusing on Asia regions. | 2008 | rebrightpartners.com | ||
Tech investment firm offering venture capital and support to startups in AI and related fields. | 2013 | finsightvc.com | New York, United States | |
Seed to late-stage venture capital investments are made in Japan. | msivc.co.jp | Tokyo, Japan |
Investor details for MediBuddy
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Medi Assist Healthcare Services Limited (MediBuddy)
Medi Assist Healthcare Services Limited is the primary company behind MediBuddy. The boards of the 2 registered companies of MediBuddy currently have 14 directors; the longest-serving is Vikram Jit Singh Chhatwal, appointed in 2010. 35 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vikram Jit Singh Chhatwal DIN 01606329 | Director | 15 Nov 2010 | 15 yrs 11 mo | Medi Assist Healthcare Services Limited |
| Enbasekar Dinadayalane DIN 06639696 | Director | 31 Jul 2013 | 13 yrs 2 mo | Phasorz Technologies Private Limited |
| Satish Kannan DIN 06639711 | Managing Director | 31 Jul 2013 | 13 yrs 2 mo | Phasorz Technologies Private Limited |
| Vishal Vijay Gupta DIN 01913013 | Director | 21 Aug 2018 | 8 yrs 2 mo | Phasorz Technologies Private Limited |
| Satish Gidugu DIN 06643677 | Whole-time director | 01 Apr 2020 | 6 yrs 6 mo | Medi Assist Healthcare Services Limited |
| Tirunelveli Padmanabhan Devarajan DIN 03473633 | Nominee Director | 08 Jan 2021 | 5 yrs 9 mo | Phasorz Technologies Private Limited |
| Ritu Niraj Anand DIN 00363699 | Director | 05 Mar 2021 | 5 yrs 7 mo | Medi Assist Healthcare Services Limited |
| Sunil Kumar Thakur DIN 03266370 | Nominee Director | 25 Jun 2022 | 4 yrs 3 mo | Phasorz Technologies Private Limited |
| Madhavan Ganesan DIN 01674529 | Director | 14 Nov 2024 | 1 yr 11 mo | Medi Assist Healthcare Services Limited |
| Narain Duraiswami DIN 03310642 | Director | 14 Nov 2024 | 1 yr 11 mo | Medi Assist Healthcare Services Limited |
| Alamelu Lakshmanachary Thatra DIN 07628279 | Director | 14 Nov 2024 | 1 yr 11 mo | Medi Assist Healthcare Services Limited |
| Ashwinraghav DIN 10908920 | Director | 05 Feb 2025 | 1 yr 8 mo | Medi Assist Healthcare Services Limited |
| Samir Rajendra Abhyankar DIN 10081649 | Nominee Director | 05 Jun 2025 | 1 yr 4 mo | Phasorz Technologies Private Limited |
| Sunita Rebecca Cherian DIN 10188170 | Director | 06 Feb 2026 | 8 mo | Medi Assist Healthcare Services Limited |
People of MediBuddy
97 people are tracked at MediBuddy (27 in leadership, 70 in team); the tracked headcount is 52.
| Name | Role | Group |
|---|---|---|
Enbasekar D | Co-Founder & CTO | Leadership |
| Co-Founder & CEO | Leadership | |
Mohammed Irfan | Director Of Engineering | Leadership |
Shubham Sarawagi | Director - Insurer Wellness Business | Leadership |
Sonal Gupta | Vice President | Leadership |
Sidhartha Mehra | Chief Financial Officer | Leadership |
Shanawar Hasnain | Director Of Engineering | Leadership |
Swetha Priya | Senior Director | Leadership |
Divya Saurabh | Associate Director - Sales And Partnerships (karnataka, AP & Telangana) | Leadership |
Sivareena S.l. | VP And P&l Head - Strategic Initiatives | Leadership |
Anurag Bhatnagar | Senior Vice President & Business Head | Leadership |
Karthik D R | Founder's Office | Leadership |
Jaspreet Marwa | Head Of Customer Support | Leadership |
Pratik Chouhan | Associate Vice President | Leadership |
Kuldeep Singh | Senior Vice President Of Engineering | Leadership |
Joel Fernandez | Senior Director | Leadership |
Manu Sankar Das | Senior Director - Brand Marketing, Media Buying & Consumer Insights | Leadership |
Ashok Sn | Chief Strategy And Distribution Officer | Leadership |
Sabyasachi Das | Chief - Affinity Business | Leadership |
Adnan Sayed | Associate Director Of Sales | Leadership |
77 more people are available in the full profile.
Complete people profiles for MediBuddy
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MediBuddy
MediBuddy is a publicly listed company on the NSE with ticker symbol MEDIASSIST in India, operating in the Miscellaneous sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNSE: MEDIASSIST
- Listed entityMedi Assist Healthcare Services Limited
- Exchange sectorMiscellaneous
Financials of MediBuddy
Exchange-reported figures of Medi Assist Healthcare Services Limited, the listed company behind MediBuddy (NSE: MEDIASSIST).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 905 | 723 | 635 | 505 | 394 | 323 | 319 |
| Revenue growth | +25.1% | +14.0% | +25.7% | +28.2% | +22.0% | +1.3% | - |
| EBITDA | 160 | 154 | 110 | 118 | 91.19 | 64.01 | 77.13 |
| EBITDA margin | +17.7% | +21.3% | +17.4% | +23.4% | +23.2% | +19.8% | +24.2% |
| Profit before tax | 80.35 | 112 | 82.27 | 102 | 81.44 | 49.31 | 58.75 |
| Net profit | 96.22 | 88.00 | 80.48 | 70.05 | 61.93 | 23.83 | 33.30 |
| Net profit margin | +10.6% | +12.2% | +12.7% | +13.9% | +15.7% | +7.4% | +10.5% |
| EPS (βΉ) | 12.14 | 12.89 | 9.53 | 10.76 | 9.33 | 7,101.35 | 9,601.67 |
| Balance sheet | |||||||
| Total assets | 952 | 801 | 534 | 436 | 378 | 336 | 337 |
| Net worth | 839 | 541 | 472 | 377 | 337 | 290 | 213 |
| Total debt | 54.40 | 204 | 26.33 | 30.68 | 27.48 | 35.30 | 114 |
| Cash & bank | 86.34 | 185 | 164 | 212 | 62.53 | 115 | 39.13 |
| Net working capital | 11.61 | 124 | 100 | 133 | 8.55 | 59.72 | 29.59 |
| Cash flow | |||||||
| Cash from operations | 118 | 138 | 66.38 | 81.08 | 64.40 | 139 | 18.65 |
| Cash from investing | (158) | (218) | (54.64) | (10.21) | (82.90) | (60.80) | (22.22) |
| Cash from financing | 12.20 | 112 | (14.76) | (31.53) | (30.29) | (9.79) | (11.75) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 237 | 242 | 240 | 233 | 191 | 189 | 186 | 181 |
| Revenue growth (YoY) | +24.1% | +28.1% | +28.9% | +28.6% | +13.6% | - | - | - |
| Other income | 10.50 | 2.73 | 7.56 | 2.28 | 7.29 | 7.77 | 4.47 | 6.42 |
| EBITDA | 48.02 | 48.26 | 30.42 | 39.72 | 42.01 | 40.70 | 39.69 | 38.46 |
| EBITDA margin | +20.3% | +19.9% | +12.7% | +17.1% | +22.0% | +21.5% | +21.3% | +21.3% |
| Depreciation | 21.85 | 20.95 | 21.13 | 20.93 | 14.11 | 14.11 | 14.42 | 13.54 |
| Interest | 1.76 | 2.14 | 8.39 | 7.59 | 4.67 | 4.36 | 2.49 | 1.79 |
| Profit before tax | 34.91 | 27.90 | 8.46 | 13.48 | 30.52 | 30.00 | 27.25 | 29.55 |
| Tax | 7.31 | (26.57) | 4.34 | 5.40 | 7.88 | 8.42 | (2.73) | 8.53 |
| Net profit | 27.60 | 54.47 | 4.12 | 8.08 | 22.64 | 21.58 | 29.98 | 21.02 |
| EPS (βΉ) | 3.71 | 7.33 | 0.51 | 1.12 | 3.16 | 3.04 | 4.18 | 2.97 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 225 | 151 | 108 | 63.79 | 54.65 | 54.01 | 61.89 |
| Revenue growth | +49.7% | +38.9% | +70.0% | +16.7% | +1.2% | -12.7% | - |
| EBITDA | 80.99 | 59.32 | 15.05 | 3.28 | 13.49 | 12.14 | 34.54 |
| EBITDA margin | +35.9% | +39.4% | +13.9% | +5.1% | +24.7% | +22.5% | +55.8% |
| Profit before tax | 68.77 | 44.56 | 25.51 | 18.96 | 18.07 | 42.70 | 48.97 |
| Net profit | 52.03 | 31.76 | 33.41 | 15.99 | 15.85 | 31.29 | 36.56 |
| Net profit margin | +23.1% | +21.1% | +30.8% | +25.1% | +29.0% | +57.9% | +59.1% |
| EPS (βΉ) | 7.18 | 4.71 | 2.77 | 2.41 | 2.69 | 9,463.78 | 10,274.72 |
| Balance sheet | |||||||
| Total assets | 498 | 260 | 218 | 171 | 173 | 171 | 155 |
| Net worth | 489 | 230 | 216 | 168 | 167 | 164 | 76.02 |
| Total debt | 4.80 | 15.38 | 0.94 | 2.84 | 4.58 | 5.58 | 78.30 |
| Cash & bank | 23.36 | 35.72 | 24.24 | 24.49 | 5.88 | 39.42 | 5.55 |
| Net working capital | 16.98 | 56.22 | 48.86 | 39.93 | 43.52 | 54.39 | 14.81 |
| Cash flow | |||||||
| Cash from operations | 59.27 | 62.66 | 39.87 | 24.16 | (8.31) | 24.35 | (13.99) |
| Cash from investing | (253) | (49.12) | (49.42) | 7.21 | (4.36) | 28.22 | (0.48) |
| Cash from financing | 193 | (11.81) | 0.18 | (15.07) | (19.41) | (2.60) | (1.71) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 58.98 | 63.56 | 57.43 | 60.76 | 43.70 | 42.55 | 34.33 | 39.48 |
| Revenue growth (YoY) | +35.0% | +49.4% | +67.3% | +53.9% | +27.7% | - | - | - |
| Other income | 7.03 | 5.15 | 3.86 | 3.26 | 2.36 | 0.63 | 1.81 | 3.15 |
| Total expenses | 42.32 | 39.60 | 39.84 | 35.75 | 29.27 | 22.44 | 26.97 | 22.16 |
| EBITDA | 16.66 | 23.96 | 17.59 | 25.01 | 14.43 | 20.11 | 7.36 | 17.32 |
| EBITDA margin | +28.2% | +37.7% | +30.6% | +41.2% | +33.0% | +47.3% | +21.4% | +43.9% |
| Depreciation | 4.88 | 5.13 | 5.13 | 5.00 | 5.07 | 4.99 | 4.69 | 4.75 |
| Interest | 1.11 | 4.58 | 0.62 | 0.46 | 0.87 | 0.96 | 0.85 | 0.90 |
| Profit before tax | 17.70 | 19.40 | 15.70 | 22.81 | 10.85 | 14.79 | 3.63 | 14.82 |
| Tax | 4.55 | 4.91 | 3.87 | 5.18 | 2.83 | 4.06 | (0.04) | 4.69 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 237 | 242 | 240 | 233 | 191 | 189 | 186 | 181 |
| Revenue growth (YoY) | +24.1% | +28.1% | +28.9% | +28.6% | +13.6% | - | - | - |
| Other income | 10.50 | 2.73 | 7.56 | 2.28 | 7.29 | 7.77 | 4.47 | 6.42 |
| EBITDA | 48.02 | 48.26 | 30.42 | 39.72 | 42.01 | 40.70 | 39.69 | 38.46 |
| EBITDA margin | +20.3% | +19.9% | +12.7% | +17.1% | +22.0% | +21.5% | +21.3% | +21.3% |
| Depreciation | 21.85 | 20.95 | 21.13 | 20.93 | 14.11 | 14.11 | 14.42 | 13.54 |
| Interest | 1.76 | 2.14 | 8.39 | 7.59 | 4.67 | 4.36 | 2.49 | 1.79 |
| Profit before tax | 34.91 | 27.90 | 8.46 | 13.48 | 30.52 | 30.00 | 27.25 | 29.55 |
| Tax | 7.31 | (26.57) | 4.34 | 5.40 | 7.88 | 8.42 | (2.73) | 8.53 |
| Net profit | 27.60 | 54.47 | 4.12 | 8.08 | 22.64 | 21.58 | 29.98 | 21.02 |
| EPS (βΉ) | 3.71 | 7.33 | 0.51 | 1.12 | 3.16 | 3.04 | 4.18 | 2.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 905 | 723 | 635 | 505 | 394 | 323 | 319 |
| Revenue growth | +25.1% | +14.0% | +25.7% | +28.2% | +22.0% | +1.3% | - |
| Other income | 19.64 | 23.76 | 18.32 | 14.02 | 21.61 | 22.55 | 11.82 |
| Total expenses | 744 | 569 | 525 | 387 | 303 | 259 | 241 |
| Employee cost | 0.00 | 306 | 255 | 198 | 156 | 143 | 135 |
| EBITDA | 160 | 154 | 110 | 118 | 91.19 | 64.01 | 77.13 |
| EBITDA margin | +17.7% | +21.3% | +17.4% | +23.4% | +23.2% | +19.8% | +24.2% |
| Depreciation | 77.13 | 55.78 | 43.08 | 26.77 | 28.41 | 31.52 | 26.51 |
| Interest | 22.57 | 10.30 | 3.17 | 2.99 | 2.95 | 5.73 | 3.69 |
| Profit before tax | 80.35 | 112 | 82.27 | 102 | 81.44 | 49.31 | 58.75 |
| Tax | (8.95) | 20.19 | 13.09 | 28.30 | 17.22 | 23.03 | 24.19 |
| Net profit | 96.22 | 88.00 | 80.48 | 70.05 | 61.93 | 23.83 | 33.30 |
| Net profit margin | +10.6% | +12.2% | +12.7% | +13.9% | +15.7% | +7.4% | +10.5% |
| EPS (βΉ) | 12.14 | 12.89 | 9.53 | 10.76 | 9.33 | 7,101.35 | 9,601.67 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 37.31 | 35.26 | 35.11 | 34.43 | 34.43 | 0.04 | 0.21 |
| Reserves & surplus | 764 | 468 | 398 | 301 | 258 | 248 | 212 |
| Shareholders' funds (net worth) | 839 | 541 | 472 | 377 | 337 | 290 | 213 |
| Minority interest | 13.50 | 10.69 | 9.59 | 7.06 | 2.16 | 2.16 | 2.16 |
| Secured loans | 0.00 | 150 | 0.00 | 0.00 | 0.00 | 0.00 | 19.45 |
| Unsecured loans | 54.40 | 53.62 | 26.33 | 30.68 | 27.48 | 35.30 | 95.05 |
| Total debt | 54.40 | 204 | 26.33 | 30.68 | 27.48 | 35.30 | 114 |
| Total liabilities | 952 | 801 | 534 | 436 | 378 | 336 | 337 |
| Assets | |||||||
| Gross block | 945 | 533 | 437 | 319 | 237 | 231 | 233 |
| Net block | 639 | 306 | 246 | 171 | 98.70 | 119 | 138 |
| Capital work in progress | 19.44 | 3.87 | 3.01 | 0.00 | 6.46 | 0.69 | 1.38 |
| Investments | 158 | 274 | 76.83 | 44.00 | 201 | 111 | 71.92 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 287 | 221 | 179 | 127 | 119 | 121 | 67.88 |
| Cash & bank balances | 86.34 | 185 | 164 | 212 | 62.53 | 115 | 39.13 |
| Loans & advances | 59.41 | 73.91 | 66.19 | 60.73 | 51.50 | 32.81 | 144 |
| Total current assets | 432 | 480 | 409 | 399 | 233 | 269 | 251 |
| Total current liabilities | 421 | 357 | 308 | 267 | 224 | 209 | 222 |
| Net working capital | 11.61 | 124 | 100 | 133 | 8.55 | 59.72 | 29.59 |
| Total assets | 952 | 801 | 534 | 436 | 378 | 336 | 337 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 83.01 | 50.93 | 53.94 | 14.60 | 63.39 | (5.46) | 9.87 |
| Net cash from operating activities | 118 | 138 | 66.38 | 81.08 | 64.40 | 139 | 18.65 |
| Net cash from investing activities | (158) | (218) | (54.64) | (10.21) | (82.90) | (60.80) | (22.22) |
| Net cash from financing activities | 12.20 | 112 | (14.76) | (31.53) | (30.29) | (9.79) | (11.75) |
| Net change in cash | (28.38) | 32.09 | (3.02) | 39.35 | (48.79) | 68.85 | (15.32) |
| Closing cash | 86.34 | 185 | 164 | 212 | 62.53 | 115 | 39.13 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +25.1% | +14.0% | +25.7% | +28.2% | +22.0% | +1.3% | - |
| EBITDA growth | +4.1% | +39.8% | -6.7% | +29.5% | +42.5% | -17.0% | - |
| PBT growth | -28.1% | +35.8% | -19.6% | +25.7% | +65.2% | -16.1% | +42.3% |
| Net income growth | +9.3% | +9.3% | +14.9% | +13.1% | +159.9% | -28.4% | - |
| Revenue CAGR (3Y) | +21.5% | +22.5% | +25.3% | +16.6% | +12.5% | - | - |
| EBITDA CAGR (3Y) | +10.8% | +19.1% | +19.9% | +15.3% | +12.3% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +9.9% | +12.7% | +10.9% | +14.7% | +16.3% | +8.1% | +10.9% |
| Return on capital employed | - | +18.6% | +22.5% | +26.2% | +23.8% | +18.2% | +19.0% |
| Return on net worth | - | +18.1% | +19.5% | +20.8% | +20.5% | +9.5% | +16.1% |
| Debt / equity | - | 0.23 | 0.07 | 0.08 | 0.10 | 0.30 | 0.49 |
| Long-term debt / equity | - | 0.07 | 0.04 | 0.05 | 0.07 | 0.12 | 0.17 |
| Interest cover | 27.10 | 10.48 | 4.72 | 3.27 | 4.70 | 17.64 | 7.29 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.49 | 1.68 | 1.82 | 1.68 | 1.39 | 1.43 |
| Inventory turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | - | 3.62 | 4.15 | 4.11 | 3.28 | 3.42 | 4.03 |
| EPS (βΉ) | 12.14 | 12.89 | 9.53 | 10.76 | 9.33 | 7,101.35 | 9,601.67 |
| Dividend per share (βΉ) | 2.00 | 0.00 | 2.50 | 1.89 | 1.89 | 0.00 | 0.00 |
| Book value per share (βΉ) | 0.00 | 71.40 | 61.68 | 48.69 | 42.44 | 66,981.89 | 59,010.28 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 58.98 | 63.56 | 57.43 | 60.76 | 43.70 | 42.55 | 34.33 | 39.48 |
| Revenue growth (YoY) | +35.0% | +49.4% | +67.3% | +53.9% | +27.7% | - | - | - |
| Other income | 7.03 | 5.15 | 3.86 | 3.26 | 2.36 | 0.63 | 1.81 | 3.15 |
| Total expenses | 42.32 | 39.60 | 39.84 | 35.75 | 29.27 | 22.44 | 26.97 | 22.16 |
| EBITDA | 16.66 | 23.96 | 17.59 | 25.01 | 14.43 | 20.11 | 7.36 | 17.32 |
| EBITDA margin | +28.2% | +37.7% | +30.6% | +41.2% | +33.0% | +47.3% | +21.4% | +43.9% |
| Depreciation | 4.88 | 5.13 | 5.13 | 5.00 | 5.07 | 4.99 | 4.69 | 4.75 |
| Interest | 1.11 | 4.58 | 0.62 | 0.46 | 0.87 | 0.96 | 0.85 | 0.90 |
| Profit before tax | 17.70 | 19.40 | 15.70 | 22.81 | 10.85 | 14.79 | 3.63 | 14.82 |
| Tax | 4.55 | 4.91 | 3.87 | 5.18 | 2.83 | 4.06 | (0.04) | 4.69 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 225 | 151 | 108 | 63.79 | 54.65 | 54.01 | 61.89 |
| Revenue growth | +49.7% | +38.9% | +70.0% | +16.7% | +1.2% | -12.7% | - |
| Other income | 14.63 | 7.67 | 22.17 | 21.71 | 13.51 | 44.59 | 24.89 |
| Total expenses | 144 | 91.27 | 93.37 | 60.51 | 41.16 | 41.87 | 27.35 |
| Employee cost | 0.00 | 24.76 | 20.51 | 19.64 | 15.16 | 25.34 | 14.49 |
| EBITDA | 80.99 | 59.32 | 15.05 | 3.28 | 13.49 | 12.14 | 34.54 |
| EBITDA margin | +35.9% | +39.4% | +13.9% | +5.1% | +24.7% | +22.5% | +55.8% |
| Depreciation | 20.32 | 18.80 | 11.52 | 5.70 | 8.47 | 10.84 | 9.89 |
| Interest | 6.53 | 3.63 | 0.19 | 0.33 | 0.46 | 3.19 | 0.57 |
| Profit before tax | 68.77 | 44.56 | 25.51 | 18.96 | 18.07 | 42.70 | 48.97 |
| Tax | 16.78 | 11.35 | 6.05 | 2.37 | (0.43) | 7.69 | 11.98 |
| Net profit | 52.03 | 31.76 | 33.41 | 15.99 | 15.85 | 31.29 | 36.56 |
| Net profit margin | +23.1% | +21.1% | +30.8% | +25.1% | +29.0% | +57.9% | +59.1% |
| EPS (βΉ) | 7.18 | 4.71 | 2.77 | 2.41 | 2.69 | 9,463.78 | 10,274.72 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 37.31 | 35.26 | 35.11 | 34.43 | 34.43 | 0.04 | 0.04 |
| Reserves & surplus | 408 | 150 | 135 | 85.27 | 125 | 159 | 70.40 |
| Shareholders' funds (net worth) | 489 | 230 | 216 | 168 | 167 | 164 | 76.02 |
| Secured loans | 0.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.45 |
| Unsecured loans | 4.80 | 5.38 | 0.94 | 2.84 | 4.58 | 5.58 | 58.85 |
| Total debt | 4.80 | 15.38 | 0.94 | 2.84 | 4.58 | 5.58 | 78.30 |
| Total liabilities | 498 | 260 | 218 | 171 | 173 | 171 | 155 |
| Assets | |||||||
| Gross block | 154 | 147 | 81.90 | 76.25 | 62.85 | 60.79 | 56.84 |
| Net block | 52.52 | 64.51 | 17.37 | 23.24 | 9.55 | 15.89 | 22.55 |
| Capital work in progress | 19.44 | 3.87 | 3.01 | 0.00 | 6.46 | 0.69 | 1.38 |
| Investments | 173 | 120 | 133 | 95.28 | 103 | 94.04 | 87.75 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 33.89 | 23.93 | 15.47 | 12.81 | 35.76 | 30.66 | 9.93 |
| Cash & bank balances | 23.36 | 35.72 | 24.24 | 24.49 | 5.88 | 39.42 | 5.55 |
| Loans & advances | 12.47 | 67.87 | 43.02 | 28.81 | 24.23 | 20.76 | 59.23 |
| Total current assets | 69.72 | 128 | 82.73 | 66.11 | 65.87 | 90.84 | 74.71 |
| Total current liabilities | 52.74 | 71.30 | 33.87 | 26.18 | 22.35 | 36.45 | 59.90 |
| Net working capital | 16.98 | 56.22 | 48.86 | 39.93 | 43.52 | 54.39 | 14.81 |
| Total assets | 498 | 260 | 218 | 171 | 173 | 171 | 155 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 12.09 | 10.36 | 19.72 | 3.43 | 35.51 | (14.45) | 1.72 |
| Net cash from operating activities | 59.27 | 62.66 | 39.87 | 24.16 | (8.31) | 24.35 | (13.99) |
| Net cash from investing activities | (253) | (49.12) | (49.42) | 7.21 | (4.36) | 28.22 | (0.48) |
| Net cash from financing activities | 193 | (11.81) | 0.18 | (15.07) | (19.41) | (2.60) | (1.71) |
| Net change in cash | (0.73) | 1.73 | (9.37) | 16.30 | (32.08) | 49.96 | (16.17) |
| Closing cash | 23.36 | 35.72 | 24.24 | 24.49 | 5.88 | 39.42 | 5.55 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +49.7% | +38.9% | +70.0% | +16.7% | +1.2% | -12.7% | - |
| EBITDA growth | +36.5% | +294.2% | +358.8% | -75.7% | +11.1% | -64.9% | - |
| PBT growth | +54.3% | +74.7% | +34.6% | +4.9% | -57.7% | -12.8% | +517.5% |
| Net income growth | +63.8% | -4.9% | +108.9% | +0.9% | -49.3% | -14.4% | - |
| Revenue CAGR (3Y) | +52.3% | +40.2% | +26.2% | +1.0% | +1.3% | - | - |
| EBITDA CAGR (3Y) | +191.2% | +63.8% | +7.4% | -54.4% | -1.1% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +23.1% | +22.1% | +18.0% | +26.0% | +33.9% | +64.8% | +59.8% |
| Return on capital employed | - | +20.2% | +24.4% | +11.2% | +8.9% | +25.0% | +32.6% |
| Return on net worth | - | +14.9% | +17.4% | +9.9% | +9.6% | +26.1% | +43.4% |
| Debt / equity | - | 0.04 | 0.01 | 0.02 | 0.03 | 0.35 | 0.84 |
| Long-term debt / equity | - | 0.03 | 0.00 | 0.01 | 0.02 | 0.04 | 0.03 |
| Interest cover | 10.76 | 8.96 | 5.38 | -13.64 | 9.16 | 245.38 | 2.31 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.32 | 1.37 | 0.92 | 0.88 | 0.92 | 1.21 |
| Inventory turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | - | 7.64 | 7.67 | 2.63 | 1.65 | 2.66 | 2.57 |
| EPS (βΉ) | 7.18 | 4.71 | 2.77 | 2.41 | 2.69 | 9,463.78 | 10,274.72 |
| Dividend per share (βΉ) | 2.00 | 0.00 | 2.50 | 1.89 | 1.89 | 0.00 | 0.00 |
| Book value per share (βΉ) | 0.00 | 26.23 | 24.24 | 17.38 | 23.13 | 42,861.35 | 19,566.11 |
Investments & Acquisitions by MediBuddy
MediBuddy has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Clinix and MediBuddy VHealth.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Various healthcare services are provided via an online subscription platform. | vhealth.io | Delhi, India | 2008 | Feb 2023 | β’β’β’β’ | |
Online consultations with multi-specialty doctors are facilitated via digital platforms. | clinix.co.in | Hyderabad, India | 2021 | Jul 2022 | β’β’β’β’ |
Complete acquisition details for MediBuddy
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MediBuddy
7 dated milestones of MediBuddy across 13 years, from founding to its latest funding, stage changes and deals.
- Founded MediBuddy is founded.
- Funding First funding round of $233K.
- Milestone Reaches Minicorn status.
- Exit Acquired by DocsApp.
- Acquisition Acquires Clinix.
- Acquisition Acquires MediBuddy VHealth.
- Funding Latest funding round, Series C, of $5.9M.
Competitors of MediBuddy
MediBuddy has 3 listed competitors in our database, 3 of them funded. They include Practo, API Holdings and Mfine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| practo.com | 2008 | Bengaluru, India | $227.88M | Doctor appointments are booked and healthcare professionals are consulted online. | ||
| apiholdings.in | 2012 | Mumbai, India | $1.19B | 221 | Digital healthcare tools are offered for pharmacies and clinics management. | |
| mfine.co | 2017 | Bengaluru, India | $87.66M | 258 | Provider of online doctor consultations, at-home lab tests, and health packages |
Detailed competitors of MediBuddy
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MediBuddy
The website of MediBuddy (medibuddy.in) receives about 1.4M visits a month and ranks #38,660 among all websites worldwide, #2,447 in Insurance.
- Monthly visits1.4M
▼ 1.5% vs previous month
- Unique visitors720.8K
per month
- Global rank#38,660
among all websites
- Category rank#2,447
Finance · Insurance
- Bounce rate33%
- Pages per visit3.3
- Average visit1 min 55 sec
- DevicesDesktop 21% Β· Mobile 79%
Websites whose visitors overlap most with MediBuddy. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mediassisttpa.in | 100% | #143,942 | View details | ||
| mediassist.in | 81% | 1.9M | #23,387 | View details | |
| truemeds.in | 79% | 5.5M | #12,844 | View details | |
| apollo247.com | 78% | 2.5M | #26,447 | View details | |
| healthindiatpa.com | 75% | 106.7K | #416,909 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 40 similar websites and full traffic analytics for MediBuddy
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Digital Health & Telemedicine
2 companies that operate in the same segment as MediBuddy (Digital Health & Telemedicine) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of an online pharmacy with doctor listing and teleconsultation services | 2015 | Delhi, Delhi, India | USD 230.8 M | USD 328.97 M | 5,212 | |
An online marketplace for healthcare products is operated. | 2011 | Kolkata, West Bengal, India | USD 38.26 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medibuddy
Complete news archive for MediBuddy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MediBuddy
MediBuddy was founded in 2013 and raised its 1st funding round 1 year after it was founded.
MediBuddy is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Satish Kannan is the CEO of MediBuddy, as recorded in our data. They have also founded this company.
MediBuddy is a funded company, having raised a total of $199.22M across 15 funding rounds to date. The company's 1st funding round was a Series A of $6.03M, raised on Mar 2014.
MediBuddy has 52 employees.
The primary company behind MediBuddy, Medi Assist Healthcare Services Limited, reported revenue of βΉ924 Cr for FY 2026, up 25% year on year.
Online platform offering multiple healthcare services. The platform enables users to search for healthcare providers and schedule follow-ups with doctors across multiple medical specialties. Also, it enables users to access medicine delivery, lab tests, health check-up, and insurance services.
MediBuddy's top competitors include Practo, API Holdings and Mfine.
Yes, MediBuddy is publicly traded on NSE under the ticker symbol MEDIASSIST.
MediBuddy has made 2 acquisitions, including Clinix, and MediBuddy VHealth.
MediBuddy has 53 investors. Key investors include DeNA, Bessemer Venture Partners, DocsApp, Quadria Capital, and Alteria Capital.
The valuation of MediBuddy is $418.14M as of Feb 2023.

